“以油养肤”开创者林清轩获证监会备案 冲刺港股“国货高端护肤第一股”

Core Viewpoint - Lin Qingxuan is advancing its IPO process in Hong Kong, aiming to become the leading domestic high-end skincare brand listed in the market, leveraging its unique product offerings and competitive advantages in the industry [1][3]. Group 1: Company Overview - Lin Qingxuan plans to issue up to 16.061 million overseas listed shares and list on the Hong Kong Stock Exchange, marking a significant step in its IPO journey [1]. - The company is recognized as the top domestic high-end skincare brand in China, particularly noted for its signature product, Camellia Oil, which has established a strong market presence [1][2]. - Lin Qingxuan is the only domestic brand among the top 15 high-end skincare brands in China, which includes international competitors [1]. Group 2: Financial Performance - From 2022 to 2024, Lin Qingxuan's revenue is projected to grow from 691 million RMB to 1.21 billion RMB, reflecting a compound annual growth rate (CAGR) of 32.3%, significantly outpacing the industry average [2]. - The flagship product, Camellia Oil, has sold over 30 million bottles since its launch in 2014, maintaining its position as the retail sales champion in the facial oil category for 11 consecutive years [2]. Group 3: Research and Development - Lin Qingxuan has invested heavily in R&D, with expenses increasing from 21.12 million RMB in 2022 to 30.4 million RMB in 2024, resulting in 80 patents, including 42 related to core ingredients and technologies [2]. - The flagship patented ingredient, Qingxuan Extract, derived from high-altitude red camellia flowers, offers targeted skin benefits, enhancing skin elasticity and reducing fine lines [2]. Group 4: Market Strategy - The company is redefining high-end domestic skincare through comprehensive control over its supply chain and an OMO (Online-Merge-Offline) sales model, which positions it well for future growth and global expansion [3].